Payment overview · 2025
General Payments
$152.96
8 reported records · 5 companies
Healthcare provider profile · identity verified
Walter D. Toronjo, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HUNTSVILLE, TX · NPI 1992720387
Verified facts
What the public records show
CMS Open Payments records show Walter D. Toronjo, M.D. received $152.96 in general payments during 2025 across 8 reported records.
Lilly USA, LLC accounted for 34.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.62 | 34.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.85 | 23.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.97 | 15.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.83 | 14.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.69 | 12.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $152.96 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $37.21 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $35.85 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 575 | 174 |
| Lisinopril | Lisinopril | 549 | 180 |
| Montelukast Sodium | Montelukast Sodium | 460 | 195 |
| Atorvastatin Calcium | Atorvastatin Calcium | 457 | 145 |
| Hydrochlorothiazide | Hydrochlorothiazide | 456 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 437 | 128 |
| Simvastatin | Simvastatin | 421 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 420 | 137 |
| Metformin Hcl | Metformin Hcl | 402 | 127 |
| Methylprednisolone | Methylprednisolone | 362 | 267 |
| Losartan Potassium | Losartan Potassium | 328 | 104 |
| Celecoxib | Celecoxib | 303 | 124 |
| Omeprazole | Omeprazole | 195 | 65 |
| Farxiga | Dapagliflozin Propanediol | 188 | 44 |
| Furosemide | Furosemide | 184 | 85 |
| Azithromycin | Azithromycin | 183 | 150 |
| Hydralazine Hcl | Hydralazine Hcl | 174 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 156 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 46 |
| Tramadol Hcl | Tramadol Hcl | 137 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 44 |
| Sertraline Hcl | Sertraline Hcl | 128 | 39 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 118 | 72 |
| Eliquis | Apixaban | 108 | 31 |
| Januvia | Sitagliptin Phosphate | 102 | 24 |
| Pregabalin | Pregabalin | 102 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 101 | 37 |
| Glyburide | Glyburide | 99 | 32 |
| Glimepiride | Glimepiride | 93 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 89 | 75 |
| Gabapentin | Gabapentin | 87 | 40 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 83 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 28 |
| Clonidine Hcl | Clonidine Hcl | 78 | 40 |
| Potassium Chloride | Potassium Chloride | 78 | 28 |
| Ozempic | Semaglutide | 75 | 15 |
| Xarelto | Rivaroxaban | 73 | 17 |
| Allopurinol | Allopurinol | 71 | 23 |
| Sucralfate | Sucralfate | 69 | 52 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 67 | 51 |
| Synthroid | Levothyroxine Sodium | 66 | 16 |
| Carvedilol | Carvedilol | 60 | 22 |
| Alprazolam | Alprazolam | 59 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 15 |
| Metformin Hcl Er | Metformin Hcl | 57 | 16 |
| Mupirocin | Mupirocin | 57 | 49 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 57 | 17 |
| Glipizide Er | Glipizide | 56 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 54 | 54 |
| Glipizide | Glipizide | 52 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 20 |
| Trazodone Hcl | Trazodone Hcl | 51 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | suppressed |
| Finasteride | Finasteride | 45 | 11 |
| Atenolol | Atenolol | 44 | 14 |
| Clonidine | Clonidine | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 15 |
| Valacyclovir | Valacyclovir Hcl | 41 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 19 |
| Meloxicam | Meloxicam | 38 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 13 |
| Colchicine | Colchicine | 37 | 21 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | 11 |
| Levofloxacin | Levofloxacin | 34 | 27 |
| Nitroglycerin Patch | Nitroglycerin | 34 | suppressed |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Metronidazole | Metronidazole | 32 | 27 |
| Meclizine Hcl | Meclizine Hcl | 31 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Famotidine | Famotidine | 30 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | 12 |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 29 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Lorazepam | Lorazepam | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Repatha Syringe | Evolocumab | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 17 |
| Indomethacin | Indomethacin | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 17 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | 11 |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Pulmicort Flexhaler | Budesonide | 12 | 12 |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | 11 |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $152.96 · 8 records | Lilly USA, LLC | Dexcom G6 Transmitter, GEMTESA, JARDIANCE, MOUNJARO, The Cologuard Plus Collection Kit, WaveWriter Alpha Prime 16, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error